Literature DB >> 11980650

Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model.

Rong Zhou1, Richard Mazurchuk, Robert M Straubinger.   

Abstract

Increased neovascularization and vascular hyperpermeability are integral processes in tumors, and various therapeutic strategies seek to reverse the angiogenic phenotype. Long-circulating liposomes extravasate in tumors such as the rat 9L gliosarcoma and accumulate in perivascular areas. Under such conditions, liposome-encapsulated doxorubicin (DOX) provides approximately 30% increase in life span, but free DOX is no more beneficial than a saline control. However, the relationship between drug deposition and therapeutic effect is understood poorly. In the present work, magnetic resonance (MR) and functional MR (fMR) imaging were used for noninvasive, serial evaluation of intracranial 9L tumor responses to repetitive doses of free DOX or DOX in sterically stabilized long-circulating liposomes (SSL-DOX). After multiple doses of SSL-DOX, MR imaging revealed the induction of intratumor hemorrhage in 63-75% of rats (n = 8). No hemorrhage was observed by MR imaging after a single dose of SSL-DOX, in normal brain regions in animals treated with free DOX (n = 3) or in saline controls (n = 9). Histological sections from rats sacrificed immediately after MR imaging verified the putative hemorrhagic regions and revealed necrotic and apoptotic tumor cells surrounding the area of the hemorrhage. fMR maps were obtained by comparing paired images acquired during air and Carbogen (7% CO2 and 93% oxygen) breathing. These blood oxygenation level-dependent fMR maps showed enhanced image intensity after both single and multiple doses of SSL-DOX, which suggested increased and progressive vascular permeabilization. The results suggest that the breakdown of tumor vasculature induced by SSL-DOX may arise from the perivascular accumulation of liposomes in tumor and cytotoxic effects on tumor vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980650

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.

Authors:  Muna Aryal; Natalia Vykhodtseva; Yong-Zhi Zhang; Nathan McDannold
Journal:  J Control Release       Date:  2015-02-24       Impact factor: 9.776

2.  Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.

Authors:  Robert D Arnold; Donald E Mager; Jeanine E Slack; Robert M Straubinger
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

3.  Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.

Authors:  Silke Glage; Andrew L Lewis; Patricia Mertens; Steffen Baltes; Peter Geigle; Thomas Brinker
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

4.  Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model.

Authors:  Tista Roy Chaudhuri; Ninfa L Straubinger; Rosemarie F Pitoniak; Bonnie L Hylander; Elizabeth A Repasky; Wen Wee Ma; Robert M Straubinger
Journal:  Mol Cancer Ther       Date:  2015-10-29       Impact factor: 6.261

5.  Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.

Authors:  Yoji Yamashita; Michal T Krauze; Tomohiro Kawaguchi; Charles O Noble; Daryl C Drummond; John W Park; Krystof S Bankiewicz
Journal:  Neuro Oncol       Date:  2006-10-03       Impact factor: 12.300

6.  Molecular magnetic resonance imaging approaches used to aid in the understanding of the tissue regeneration marker Met in vivo: implications for tissue engineering.

Authors:  Rheal A Towner; Nataliya Smith; Yasuko Asano; Sabrina Doblas; Debra Saunders; Robert Silasi-Mansat; Florea Lupu
Journal:  Tissue Eng Part A       Date:  2010-02       Impact factor: 3.845

7.  Nano to micro delivery systems: targeting angiogenesis in brain tumors.

Authors:  Ariel Gilert; Marcelle Machluf
Journal:  J Angiogenes Res       Date:  2010-10-08

Review 8.  Brain endothelial cells as pharmacological targets in brain tumors.

Authors:  Michel Demeule; Anthony Régina; Borhane Annabi; Yanick Bertrand; Michel W Bojanowski; Richard Béliveau
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

9.  Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.

Authors:  Rong Zhou; Richard V Mazurchuk; Judith H Tamburlin; John M Harrold; Donald E Mager; Robert M Straubinger
Journal:  J Pharmacol Exp Ther       Date:  2009-10-27       Impact factor: 4.030

10.  Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model.

Authors:  Muna Aryal; Natalia Vykhodtseva; Yong-Zhi Zhang; Juyoung Park; Nathan McDannold
Journal:  J Control Release       Date:  2013-04-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.